الإحصائيات الأساسية
| LEI | 549300VWSLMYAANYZ711 |
| CIK | 1611747 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biondvax Pharmaceuticals Ltd - ADR
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 4, 2025 |
As filed with the United States Securities and Exchange Commission on September 4, 2025. As filed with the United States Securities and Exchange Commission on September 4, 2025. |
|
| September 2, 2025 |
Exhibit 99.1 Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet JERUSALEM, Sept. 2, 2025 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai”, or the “Company”), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I |
|
| September 2, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS Operating Results The information contained in this section should be read in conjunction with our unaudited condensed consolidated financial statements for the six months ended June 30, 2025 and related notes and the information contained elsewhere in this Form 6-K. Our financial statements have been prepared in accordance with United Stat |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| September 2, 2025 |
SCINAI IMMUNOTHERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2025 Exhibit 99.2 SCINAI IMMUNOTHERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2025 Unaudited SCINAI IMMUNOTHERAPEUTICS LTD CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands June 30, December 31, 2025 2024 Unaudited Audited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 989 $ 1,964 Restricted cash 142 131 Prepaid expenses and other receivables 236 213 Trade receivables 13 |
|
| June 12, 2025 |
Exhibit 99.1 Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM, June 12, 2025 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| June 5, 2025 |
EX-99.1 2 ea024484001ex99-1scinai.htm PRESS RELEASE DATED JUNE 5, 2025 Exhibit 99.1 Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| June 5, 2025 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-285547 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated March 12, 2025) Scinai Immunotherapeutics Ltd. 3,022,796 AMERICAN DEPOSITARY SHARES REPRESENTING 12,091,184,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of March 12, 2025 (as supp |
|
| June 2, 2025 |
Exhibit 99.1 Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn JERUSALEM, May 30th, 2025 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related dise |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| May 12, 2025 |
As filed with the United States Securities and Exchange Commission on May 12, 2025. As filed with the United States Securities and Exchange Commission on May 12, 2025. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| May 7, 2025 |
Exhibit 13.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) In connection with the Annual Report on Form 20-F of Scinai Immunotherapeutics Ltd. (the “Company”) for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Am |
|
| May 7, 2025 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 This section summarizes certain information regarding the ordinary shares, no par value (the “Ordinary Shares”), of BiondVax Pharmaceuticals Ltd. (the “Company”) and the American Depositary Shares (“ADSs”), each representing 40 Ordinary Shares. The following descriptions are a summary and |
|
| May 7, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-271293 and No. 333-239344 ) pertaining to the 2005 Israeli Share Option Plan and the 2018 Israeli Share Option Plan and on Form F-3 (No. 333-274078 and No. 333-276767) of Scinai Immunotherapeutics Ltd. of our report dated April 17, 2 |
|
| May 7, 2025 |
Exhibit 4.16 [Unofficial Translation from Hebrew Original] Addendum 2 to the Lease Agreement of July 10, 2017 Prepared and signed in Tel Aviv on June 3, 2023 between Minrav Group Ltd. 52-0034505 (Formerly Unihead Biopark Ltd.) Raoul Wallenberg Street 24, Ziv Tower, Building D, Tel Aviv (“the Company”) On the one hand; And BiondVax Pharmaceuticals Ltd. 51346105 From Building Minrav Campus Hadassah |
|
| May 7, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (Nos. 333-271293 and 333-239344) and Forms F-3 (Nos. 333-274078 and 333-276767) of Scinai Immunotherapeutics Ltd. of our report dated May 7, 2025, relating to the financial statements which appears in Scinai Immunotherapeutics Ltd.’s |
|
| May 7, 2025 |
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amir Reichman, certify that: 1. I have reviewed this report on Form 20-F of Scinai Immunotherapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w |
|
| May 7, 2025 |
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Uri Ben-Or, certify that: 1. I have reviewed this report on Form 20-F of Scinai Immunotherapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whic |
|
| May 7, 2025 |
Exhibit 4.29 CERTAIN IDENTIFIED INFORMATION MARKED ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. BINDING option AGREEMENT CONCERNING THE SALE AND transfer OF ALL QUOTA IN Pincell s.r.l. between [***] the Sellers and PinCell S.r.l. as Company and Scinai Immunotherapeutics sp. z.o.o. as Scinai SPV and S |
|
| May 7, 2025 |
Exhibit 1.1 COMPANIES LAW, 5759 – 1999 LIMITED SHARES COMPANY Amended and Restated Articles of Association of SCINAI IMMUNOTHERAPEUTICSLTD. 1. In these articles, except where the written content requires a different interpretation: “Law” As defined in the Interpretation Law, 5741 – 1981; “The Company” The abovementioned Company; “The Law” or the “Companies Law” The Companies Law, 5759 – 1999, as i |
|
| May 7, 2025 |
Exhibit 4.18 CERTAIN IDENTIFIED INFORMATION MARKED ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. [Unofficial Translation from Hebrew Original] Addendum 4 to the Lease Agreement of July 10, 2017 Prepared and signed in Tel Aviv on December 15, 2024 between Minrav Group Ltd. 52-0034505 (Formerly Unihead |
|
| May 7, 2025 |
Exhibit 4.15 [Unofficial Translation from Hebrew Original] First Addendum to the Unprotected Lease Agreement from July 10, 2017 Prepared and signed on April 29, 2022 between Minrav Group Ltd. 52-0034505 (Formerly Unihead Biopark Ltd.) Hoshem Street 3, Ashdod (“the Company”) On the one hand; And BiondVax Pharmaceuticals Ltd. 51-34361 Einstein Street 14, Ness Ziona (“the Tenant”) On the other hand; |
|
| May 7, 2025 |
Exhibit 4.17 CERTAIN IDENTIFIED INFORMATION MARKED ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. [Unofficial Translation from Hebrew Original] Addendum 3 to the Lease Agreement of July 10, 2017 Prepared and signed in Tel Aviv on July 10, 2023 between Minrav Group Ltd. 52-0034505 (Formerly Unihead Biop |
|
| May 7, 2025 |
SCINAI IMMUNOTHERAPUETICS LTD. INSIDER TRADING POLICY Exhibit 11.2 SCINAI IMMUNOTHERAPUETICS LTD. INSIDER TRADING POLICY To Employees, Consultants/Advisors and Members of the Board of Directors Summary This Insider Trading Policy is intended to prevent violations of the United States federal securities laws and regulations, and applicable Israeli laws and regulations (collectively “Applicable Laws”), and to protect Scinai Immunotherapuetics Ltd.’s (“ |
|
| May 7, 2025 |
Exhibit 4.19 [Unofficial Translation from Hebrew Original] Addendum 5 to the Lease Agreement of July 10, 2017 Prepared and signed in Tel Aviv on December 24, 2024 between Minrav Group Ltd. 52-0034505 (Formerly Unihead Biopark Ltd.) Raoul Wallenberg Street 24, Ziv Tower, Building D, Tel Aviv (“the Company” or “the Lessor”) On the one hand; And Scinai Immunotherapeutics Ltd. 51346105 (formerly Biond |
|
| May 7, 2025 |
Exhibit 13.2 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) In connection with the Annual Report on Form 20-F of Scinai Immunotherapeutics Ltd. (the “Company”) for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ur |
|
| May 7, 2025 |
Exhibit 4.3 COMPENSATION POLICY SCINAI IMMUNOTHERAPEUTICS LTD. Compensation Policy for Executive Officers and Directors (As Adopted by the Shareholders on November 21, 2024) A. Overview and Objectives 1. Introduction This document sets forth the Compensation Policy for Executive Officers and Directors (this “Compensation Policy” or “Policy”) of Scinai Immunotherapeutics Ltd. (“Scinai” or the “Comp |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-37353 CUSIP NUMBER (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2024 ¨ |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isr |
|
| March 27, 2025 |
Exhibit 99.1 Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions Scinai files an application for Euro 12 million grant to fund next stage of development ● Pincell’s monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson’s Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) ● PC11 |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isr |
|
| March 13, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-285547 PROSPECTUS Scinai Immunotherapeutics Ltd. 3,022,796 American Depositary Shares representing 12,091,184,000 Ordinary Shares This prospectus relates to the offer and sale of up to 3,022,796 American Depositary Share (“ADSs”), by YA II PN, Ltd., or YA or the Selling Shareholder, a Cayman Islands limited partnership. Each ADS represents 4,00 |
|
| March 11, 2025 |
As filed with the United States Securities and Exchange Commission on March 11, 2025. As filed with the United States Securities and Exchange Commission on March 11, 2025. |
|
| March 11, 2025 |
Scinai Immunotherapeutics Ltd. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel March 11, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Scinai Immunotherapeutics Ltd. (CIK No. 0001611747) |
|
| March 5, 2025 |
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT Exhibit 99.1 SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT JERUSALEM, March 5, 2025 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced th |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isr |
|
| March 4, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-1 (Form Type) SCINAI IMMUNOTHERAPEUTICS LTD. |
|
| March 4, 2025 |
Exhibit 10.12 CLIFFORD CHANCE LLP EXECUTION VERSION Contract numbers (FI No.): 88205 91305 Serapis No.: 2015-0572 LOAN RESTRUCTURING AGREEMENT DATED 9 AUGUST 2024 FOR EUROPEAN INVESTMENT BANK AND SCINAI IMMUNOTHERAPEUTICS LTD RELATING TO A FINANCE CONTRACT ORIGINALLY DATED 19 JUNE 2017 AS AMENDED AND RESTATED ON 20 JUNE 2019 AND AS FURTHER AMENDED ON 11 JANUARY 2021, 9 AUGUST 2022 AND 24 NOVEMBER |
|
| March 4, 2025 |
Exhibit 10.21 INVESTMENT AGREEMENT THIS INVESTMENT AGREEMENT (this “Agreement”), dated as of August 19, 2024 (the “Effective Date”), is entered into by and between RK Stone Miami, LLC, a limited liability company organized and existing under the laws of the State of Florida (“Investor”), and Scinai Immunotherapeutics Ltd., a corporation organized and existing under the laws of Israel (the “Company |
|
| March 4, 2025 |
Exhibit 21.1 Significant Subsidiaries The following is a list of our significant subsidiaries, including the state or other jurisdiction of incorporation or organization. Each of our subsidiaries listed below is wholly-owned. Name of subsidiary State or other jurisdiction of incorporation or organization Scinai Bioservices Inc. Delaware |
|
| March 4, 2025 |
As filed with the United States Securities and Exchange Commission on March 4, 2025. As filed with the United States Securities and Exchange Commission on March 4, 2025. |
|
| March 4, 2025 |
STANDBY EQUITY PURCHASE AGREEMENT Exhibit 99.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of March 3, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and SCINAI IMMUNOTHERAPEUTICS LTD., a company incorporated under the laws of Israel (the “Company”). The Investor and the Company may be referred to herein individually as |
|
| March 4, 2025 |
Exhibit 3.1 COMPANIES LAW, 5759 – 1999 LIMITED SHARES COMPANY Amended and Restated Articles of Association of SCINAI IMMUNOTHERAPEUTICSLTD. 1. In these articles, except where the written content requires a different interpretation: “Law” As defined in the Interpretation Law, 5741 – 1981; “The Company” The abovementioned Company; “The Law” or the “Companies Law” The Companies Law, 5759 – 1999, as i |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isr |
|
| March 4, 2025 |
Exhibit 10.22 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES SCINAI IMMUNOTHERAPEUTICS LTD. Number of American Depositary Shares: [] Initial Exercise Date: [] Issue Date: [] THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, RK STONE MIAMI LLC or its assigns (the |
|
| November 25, 2024 |
Exhibit 99.1 Scinai Publishes Financial Results and Provides Business Update; Shareholders’ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million JERUSALEM, November 22, 2024 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products an |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| November 14, 2024 |
SC 13G/A 1 armistice-scni093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Scinai Immunotherapeutics Ltd. (Name of Issuer) American Depositary Shares, each representing 400 Ordinary Shares, no par value (Title of Class of Securities) 09073Q303 (CUSIP Number) September 30, 2024 (Date of Even |
|
| October 15, 2024 |
Exhibit 99.2 Annual General Meeting of Scinai Immunotherapeutics Ltd. to be held November 21, 2024 For Holders as of October 15, 2024 Annual General Meeting of Scinai Immunotherapeutics Ltd. Date: November 21, 2024 See Voting Instruction On Reverse Side. Please make your marks like this: x Use pen only Directors Recommend For Against Abstain Agenda 1.a. To approve the re-election of Mr. Amir Reich |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
|
| October 15, 2024 |
Exhibit 99.1 SCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on November 21, 2024 The Annual General Meeting of Shareholders of Scinai Immunotherapeutics Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Tel Aviv, Israel on Novembe |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| September 9, 2024 |
Exhibit 99.1 Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 JERUSALEM, Aug. 15, 2024 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological product |
|
| September 9, 2024 |
Exhibit 99.2 SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.) CONDENSED FINANCIAL STATEMENTS June 30, 2024 Unaudited SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.) – (Unaudited) BALANCE SHEETS U.S. dollars in thousands June 30, December 31, 2024 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 3,076 $ 4,870 Restricted cash 13 |
|
| August 29, 2024 |
Scinai Regains Full Compliance with Nasdaq Listing Requirements Exhibit 99.1 Scinai Regains Full Compliance with Nasdaq Listing Requirements Jerusalem, ISRAEL – aUGUST 29, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; “Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that on Augus |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| August 21, 2024 |
Exhibit 99.1 Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 Jerusalem, ISRAEL – aUGUST 21, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; “Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) b |
|
| August 20, 2024 |
STONE DANIEL E. - AMENDMENT 3 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 3 to SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 SCINAI IMMUNOTHERAPEUTCS LTD. (Name of Issuer) American Depositary Shares, each representing 4,000 Ordinary Shares, no par value (Title of Class of Securities) 09073Q203 (CUSIP Number) August 19, 2024 (Date of Even |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| August 20, 2024 |
Exhibit 99.1 Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder JERUSALEM, Aug. 20, 2024 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);(“Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai B |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| August 15, 2024 |
Exhibit 99.1 Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 JERUSALEM, Aug. 15, 2024 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological product |
|
| August 13, 2024 |
Exhibit 99.1 Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity Jerusalem – aUGUST 13, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| August 12, 2024 |
6-K 1 ea0211152-6kscinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusa |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem |
|
| August 5, 2024 |
Exhibit 99.1 SCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE TO SHAREHOLDERS RE. SUPPLEMENTAL CHANGES TO PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING To Be Held on August 12, 2024 On July 8, 2024, Scinai Immunotherapeutics Ltd. (the “Company”) the Company furnished on Form 6-K (“Original Form 6-K”) to the Securities and Exchange C |
|
| August 5, 2024 |
6-K 1 ea0210633-6kscinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusa |
|
| July 15, 2024 |
Scinai Publishes Q1 2024 Financial Results and Provides Business Update Exhibit 99.1 Scinai Publishes Q1 2024 Financial Results and Provides Business Update JERUSALEM, ISRAEL – July 2, 2024 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; “Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its fina |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| July 15, 2024 |
Exhibit 99.1 Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model JERUSALEM, July 15, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the “Company”), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today an |
|
| July 8, 2024 |
Exhibit 99.1 Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements JERUSALEM, July 3, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the “Company”), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business un |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| July 8, 2024 |
Exhibit 99.1 Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity. JERUSALEM, July 8, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the “Company”), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO serv |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| July 8, 2024 |
Exhibit 99.1 SCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF EXTRAORDINARY MEETING OF SHAREHOLDERS To Be Held on August 12, 2024 An Extraordinary Meeting of Shareholders of Scinai Immunotherapeutics Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv 6701101, I |
|
| July 8, 2024 |
Exhibit 99.2 Extraordinary General Meeting of Scinai Immunotherapeutics Ltd. Date: August 12, 2024 See Voting Instruction On Reverse Side. Please make your marks like this: x Use pen only Agenda 1. To approve amendments to the Company’s articles of association to authorize the creation of preferred shares, no par value per share, of the Company (“Preferred Shares”), and to approve the issuance of |
|
| June 14, 2024 |
Exhibit 99.1 CLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | JUNE 2024 | NASDAQ: SCNI NON - CONFIDENTIAL PUBLIC INFORMATION CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “antic |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israe |
|
| June 13, 2024 |
Exhibit 99.1 Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity. Jerusalem, June 13th, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the “Company”), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services t |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israe |
|
| June 13, 2024 |
Exhibit 99.1 Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders’ Equity Requirement Jerusalem, June 7th, 2024 – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the “Company”), a biotechnology company focused on developing inflammati |
|
| May 28, 2024 |
Exhibit 99.1 Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders’ Equity listing requirements and Hearing to Present a Plan for Regaining Compliance JERUSALEM, ISRAEL – May 24th, 2024 - Scinai Immunotherapeutics Ltd. (the “Company”/Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological prod |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israe |
|
| May 16, 2024 |
Rule 424(b)(3) File No. 333-203333 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from 400 shares to 4,000 shares, effective May 21, 2024. EXHIBIT A AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents Four thousand (4,000) deposited Shares) THE BANK OF NEW YORK MELLON AMERICAN DEP |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israe |
|
| May 15, 2024 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 This section summarizes certain information regarding the ordinary shares, no par value (the “Ordinary Shares”), of BiondVax Pharmaceuticals Ltd. (the “Company”) and the American Depositary Shares (“ADSs”), each representing 40 Ordinary Shares. The following descriptions are a summary and |
|
| May 15, 2024 |
Exhibit 16.1 May 15, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington DC 20549 Ladies and Gentlemen: We have read Item 16F of in this Annual Report (Form 20-F) for the year ended December 31, 2023 of Scinai Immunotherapeutics Ltd. and are in agreement with the statements contained in the second, third and fourth paragraphs of Item 16F therein. In addition, we have no basis to |
|
| May 15, 2024 |
Exhibit 13.2 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) In connection with the Annual Report on Form 20-F of Scinai Immunotherapeutics Ltd. (the “Company”) for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ur |
|
| May 15, 2024 |
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amir Reichman, certify that: 1. I have reviewed this report on Form 20-F of Scinai Immunotherapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w |
|
| May 15, 2024 |
Exhibit 99.1 Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update JERUSALEM, ISRAEL – May 15, 2024 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; “Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices bu |
|
| May 15, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (Nos. 333-271293 and 333-239344) and Forms F-3 (Nos. 333-274078 and 333-276767) of Scinai Immunotherapeutics Ltd. of our report dated May 15, 2024 relating to the financial statements which appears in Scinai Immunotherapeutics Ltd.'s |
|
| May 15, 2024 |
SCINAI IMMUNOTHERAPEUTIC LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 SCINAI IMMUNOTHERAPEUTIC LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Scinai Immunotherapeutic Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 30, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons |
|
| May 15, 2024 |
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Uri Ben-Or, certify that: 1. I have reviewed this report on Form 20-F of Scinai Immunotherapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whic |
|
| May 15, 2024 |
Exhibit 13.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) In connection with the Annual Report on Form 20-F of Scinai Immunotherapeutics Ltd. (the “Company”) for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Am |
|
| May 15, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-239344 and No. 333-271293) pertaining to the 2005 Israeli Share Option Plan and the 2018 Israeli Share Option Plan and on Form F-3 (No. 333-274078 and No. 333-276767) of Scinai Immunotherapeutics Ltd. of our report dated April 17, 20 |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israe |
|
| May 7, 2024 |
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal Exhibit 99.1 Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance JERUSALEM – May 6th, 2024 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-37353 CUSIP NUMBER (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ |
|
| April 25, 2024 |
Exhibit 99.1 CLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | APRIL 2024 | NASDAQ: SCNI NON - CONFIDENTIAL PUBLIC INFORMATION CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anti |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isr |
|
| April 16, 2024 |
Exhibit 99.1 CLICK TO EDIT MASTER TITLE STYLE Elevating dermatological drug development through advanced inflammatory marker targeting methodology - Focus of IL - 17 in the pathophysiology of psoriasis and unmet medical need – 5th DDDS Europe, April 17, 2024 Michael P. Schön Department of Dermatology , Venereology and Allergology Lower Saxony Institute of Occupational Dermatology University Medica |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isr |
|
| March 12, 2024 |
SC 13D 1 sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 SCINAI IMMUNOTHERAPEUTICS LTD. (formerly BioindVax Pharmaceuticals Ltd.) (Name of Issuer) Ordinary ADS Shares (Title of Class of Securities) 09073Q204 (CUSIP Number) Daniel E. Stone 1200 Brickell Avenue, #1470 Miami, FL 33131 Copy to: David |
|
| February 14, 2024 |
SC 13G 1 armistice-scni123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Scinai Immunotherapeutics Ltd. (Name of Issuer) American Depositary Shares, each representing 400 Ordinary Shares, no par value (Title of Class of Securities) 09073Q204 (CUSIP Number) December 31, 2023 (Date of Event Which |
|
| February 9, 2024 |
Scinai Immunotherapeutics Ltd. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel February 9, 2024 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Scinai Immunotherapeutics Ltd. Registration Statement on Form F-3 Filed January 30, 2024 Registration No. 333-276767 Ladies and Gentlemen: |
|
| January 30, 2024 |
As filed with the Securities and Exchange Commission on January 30, 2024 As filed with the Securities and Exchange Commission on January 30, 2024 Registration No. |
|
| January 30, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) SCINAI IMMUNOTHERAPEUTICS LTD. |
|
| January 24, 2024 |
SC 13G/A 1 sc13a2.htm AMENDMENT NO. 2 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 2 to SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 SCINAI IMMUNOTHERAPEUTCS LTD. (formerly BiondVax Pharmaceuticals Ltd.) (Name of Issuer) Ordinary ADS Shares (Title of Class of Securities) 09073Q204 (CUSIP Numb |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
|
| January 18, 2024 |
Exhibit 99.1 CLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | JANUARY 2024 | NASDAQ: SCNI CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are |
|
| January 9, 2024 |
Exhibit 99.1 CLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | JANUARY 2024 | NASDAQ: SCNI CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
|
| January 4, 2024 |
Scinai Immunotherapeutics CEO Issues Letter to Shareholders Exhibit 99.1 Scinai Immunotherapeutics CEO Issues Letter to Shareholders JERUSALEM, ISRAEL – Jan. 4, 2024 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, today published a letter from its CEO, Amir Reichman, addressing the Company’s 2023 accomplishments, including successful preclinical tr |
|
| January 4, 2024 |
Exhibit 99.2 Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds JERUSALEM, ISRAEL – Jan. 4, 2024 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological therapeutic products and provision of boutique CDMO services, today announced the clo |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| January 2, 2024 |
Exhibit 99.1 Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds JERUSALEM, ISRAEL – Dec. 29, 2023 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological therapeutic products and provision of boutique CDMO services, today announced the entry into a |
|
| January 2, 2024 |
1,215,345 American Depositary Shares representing 486,138,000 Ordinary Shares PROSPECTUS SUPPLEMENT (To Prospectus Dated December 26, 2023) Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| January 2, 2024 |
1,215,345 American Depositary Shares representing 486,138,000 Ordinary Shares PROSPECTUS File No. 333-275217 Filed Pursuant to Rule 424(b)(3) 1,215,345 American Depositary Shares representing 486,138,000 Ordinary Shares This prospectus relates to the resale, from time to time, by the selling shareholders identified in this prospectus under the section “Selling Shareholders,” (the “selling shareholders”) of Scinai Immunotherapeutics Ltd. (“Scinai,” “we,” “us”, “our” or the “ |
|
| January 2, 2024 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 2, 2024 |
PROSPECTUS SUPPLEMENT (To Prospectus Dated December 16, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| January 2, 2024 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 2, 2024 |
SCINAI IMMUNOTHERAPEUTICS LTD. Exhibit 10.1 SCINAI IMMUNOTHERAPEUTICS LTD. December 29, 2023 Holder of Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Issued in [September 2023/December 2022] Re: Inducement Offer to Exercise Warrant to Purchase Ordinary Shares Represented by American Depositary Shares Issued in [September 2023/December 2022] Dear Holder: Scinai Immunotherapeutics Ltd. (the “Compan |
|
| December 26, 2023 |
Scinai Immunotherapeutics Ltd. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel December 26, 2023 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Scinai Immunotherapeutics Ltd. Registration Statement on Form F-1 Filed October 30, 2023, as amended Registration No. 333-275217 Ladies a |
|
| December 22, 2023 |
As filed with the Securities and Exchange Commission on December 22, 2023. As filed with the Securities and Exchange Commission on December 22, 2023. Registration No. 333-275217 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scinai Immunotherapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into E |
|
| December 14, 2023 |
Exhibit 99.1 Study published in Antiviral Research supports promise of Scinai Immunotherapeutics’ coronavirus NanoAb as aerosolized prophylactic and therapeutic drug Data backs use of Scinai’s aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, addressing significant medical needs JERUSALEM, ISRAEL – Dec. 11, 2023 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| December 14, 2023 |
Scinai Announces Promising Results in a Psoriatic Human Skin Model Exhibit 99.2 Scinai Announces Promising Results in a Psoriatic Human Skin Model JERUSALEM, ISRAEL – Dec. 12, 2023 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology biological products, is pleased to announce today successful preclinical trial results of its innovative anti-IL-17 VHH antibody (‘NanoAb’) as a local trea |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| November 20, 2023 |
Scinai Immunotherapeutics Regains Compliance with Nasdaq’s Stockholders’ Equity Rule Exhibit 99.1 Scinai Immunotherapeutics Regains Compliance with Nasdaq’s Stockholders’ Equity Rule JERUSALEM, ISRAEL - Nov. 20, 2023 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced today the receipt of formal notification from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity. Scinai is a biop |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| November 7, 2023 |
Exhibit 99.1 Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit JERUSALEM, Nov. 6, 2023 - via IBN - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant covering 66% of the costs of an ILS 3,536,939 (approximately US$900,000) proj |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| November 3, 2023 |
Exhibit 99.1 European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot ● Recently rebranded Scinai Immunotherapeutics shifted drug development focus from COVID-19 antibody to a novel antibody for the treatment of psoriasis and launched a CDMO business unit ● Adjusted terms being consid |
|
| November 2, 2023 |
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update Jerusalem - Oct. 31, 2023 – Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, announced the |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| October 30, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-1 (Form Type) SCINAI IMMUNOTHERAPEUTICS LTD. |
|
| October 30, 2023 |
Exhibit 3.1 COMPANIES LAW, 5759 – 1999 LIMITED SHARES COMPANY Articles of Association of SCINAI IMMUNOTHERAPEUTICS LTD. 1. In these articles, except where the written content requires a different interpretation: “Law” As defined in the Interpretation Law, 5741 – 1981; “The Company” The abovementioned Company; “The Law” or the “Companies Law” The Companies Law, 5759 – 1999, as it shall be from time |
|
| October 30, 2023 |
As filed with the Securities and Exchange Commission on October 30, 2023. As filed with the Securities and Exchange Commission on October 30, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scinai Immunotherapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant’s name into English) State of Israel 28 |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| September 22, 2023 |
Exhibit 99.1 • • • • • • • • • • • • • • • • • • • 10 15 20 30 25 40 70 60 50 85 100 Y ea s t: P i chi a pas t or i s • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • IL - 17 is a cytokine that plays a key role in the development of psoriatic lesions, which are in essence an acute, local (dermis) flareup of a chronic underlying disease . It allows for local (rather tha |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| September 20, 2023 |
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering Exhibit 99.1 Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) - via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and |
|
| September 19, 2023 |
Exhibit 1.2 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES SCINAI IMMUNOTHERAPEUTICS LTD. Number of American Depositary Shares: [ Initial Exercise Date: [], 2023 Issue Date: [], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| September 19, 2023 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2023 by and between Scinai Immunotherapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchas |
|
| September 19, 2023 |
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering Exhibit 1.5 Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) - via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious di |
|
| September 19, 2023 |
Exhibit 1.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 19, 2023 |
Exhibit 1.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 19, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-274078 PROSPECTUS SUPPLEMENT (To prospectus dated August 25, 2023) 400,000 American Depositary Shares representing 160,000,000 Ordinary Shares Pre-funded Warrants to Purchase up to 746,552 American Depositary Shares Up to 746,552 American Depositary Shares representing 298,620,800 Ordinary Shares underlying the Pre-funded Warrants We are offeri |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as: Biondvax Pharmaceuticals Ltd) (Translation of registrant’s name into English) Jerusalem BioPa |
|
| September 11, 2023 |
Exhibit 99.1 • • • • • • • • • • • • • • • • • • • 10 15 20 30 25 40 70 60 50 85 100 Y ea s t: P i chi a pas t or i s • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • “ • - - • - • - • • • • • • • • • • • 10 1 10 2 10 3 10 4 10 5 10 6 Titer [TCID 50 /g] limit of detection ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ 9 8 7 6 5 4 3 2 1 SARS - CoV - 2 RNA copies/ml B |
|
| September 7, 2023 |
Rule 424(b)(3) File No. 333-203333 Note: BiondVax Pharmaceuticals Ltd. has changed its name to Scinai Immunotherapeutics Ltd. effective September 8, 2023. EXHIBIT A AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents Four hundred (400) deposited Shares) THE BANK OF NEW YORK MELLON AMERICAN DEPOSITARY RECEIPT FOR ORDINARY SHARES, OF SCINAI IMMUNOTHERAPEUTICS LTD. (INCORPORATED UND |
|
| September 6, 2023 |
Exhibit 99.1 • • • • • • • • • • • • • • • • • • • 10 15 20 30 25 40 70 60 50 85 100 Yeast: Pichia pastoris • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • “ • - - • - • - • • • • • • • • • • • 10 1 10 2 10 3 10 4 10 5 10 6 ٓٓٓٓ Titer [TCID 50 /g] limit of detection ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ 9 8 7 6 5 4 3 2 1 SARS - CoV - 2 RNA copies/ml BALF ٓٓ ٓٓٓ |
|
| September 6, 2023 |
Exhibit 99.1 BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” JERUSALEM, Sep. 6, 2023 (GLOBE NEWSWIRE) - via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pl |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as: Biondvax Pharmaceuticals Ltd) (Translation of registrant’s name into English) Jerusalem BioPa |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as: Biondvax Pharmaceuticals Ltd) (Translation of registrant’s name into English) Jerusalem BioPa |
|
| August 28, 2023 |
Filed Pursuant to Rule 424(b)(2) Registration No. 333-274078 PROSPECTUS $150,000,000 American Depository Shares representing Ordinary Shares, Ordinary Shares, Warrants to Purchase American Depositary Shares, Subscription Rights and/or Units Offered by the Company BIONDVAX PHARMACEUTICALS LTD. We may offer and sell to the public from time to time in one or more series or issuances up to $150,000,00 |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isr |
|
| August 23, 2023 |
Exhibit 99.1 N o n c o n f i d e n t i al p r e s e n t at i o n | A u g u s t 22, 2023 This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward - looking statements . All statements, |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August, 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Kiryat Hadassah, Building 1, JBP Jerusalem, Israel 911200 (Address o |
|
| August 23, 2023 |
CORRESP 1 filename1.htm BiondVax Pharmaceuticals Ltd. Jerusalem BioPark, 2nd Floor Kiryat Hadassah, Building 1, JBP Jerusalem, Israel 9112001 August 23, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Cindy Polynice Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS BiondVax Pharmaceuticals Ltd. (CI |
|
| August 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) BIONDVAX PHARMACEUTICALSLTD. |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K/A Amendment No. 2 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Camp |
|
| August 18, 2023 |
As filed with the Securities and Exchange Commission on August 18, 2023 As filed with the Securities and Exchange Commission on August 18, 2023 Registration No. |
|
| August 18, 2023 |
BIONDVAX PHARMACEUTICALS LTD. FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 BIONDVAX PHARMACEUTICALS LTD. FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS Unaudited INDEX Page Condensed Balance Sheets 2 – 3 Condensed Statements of Operations 4 Condensed Statements of Comprehensive Loss 5 Condensed Statements of Changes in Shareholders’ Equity 6 Condensed Statements of Cash Flows 8 – 9 Notes to the condensed Financial Statements 10 – 15 - - - |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| August 14, 2023 |
BIONDVAX PHARMACEUTICALS LTD. FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS Exhibit 99.2 BIONDVAX PHARMACEUTICALS LTD. FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS Unaudited INDEX Page Condensed Balance Sheets 2 – 3 Condensed Statements of Operations 4 Condensed Statements of Comprehensive Loss 5 Condensed Statements of Changes in Shareholders’ Equity 6 Condensed Statements of Cash Flows 8 – 9 Notes to the condensed Financial Statements 10 – 15 - - - |
|
| August 14, 2023 |
BiondVax Reports Second Quarter Financial Results and Provides Business Update Exhibit 99.1 BiondVax Reports Second Quarter Financial Results and Provides Business Update Jerusalem, Israel – Aug. 11, 2023 – via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces the publication tod |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| August 11, 2023 |
BiondVax Reports Second Quarter Financial Results and Provides Business Update Exhibit 99.1 BiondVax Reports Second Quarter Financial Results and Provides Business Update Jerusalem, Israel – Aug. 11, 2023 – via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces the publication tod |
|
| August 1, 2023 |
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Exhibit 99.1 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Jerusalem, Israel – Aug. 1, 2023 - via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Isra |
|
| July 12, 2023 |
Exhibit 99.2 |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel |
|
| July 12, 2023 |
Exhibit 99.1 BIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on August 24, 2023 The Annual General Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Tel Aviv, Israel on August 24, |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel |
|
| July 5, 2023 |
Exhibit 99.1 NASDAQ: BVXV | July 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intende |
|
| July 5, 2023 |
Exhibit 99.1 BIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on August 24, 2023 The Annual General Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Tel Aviv, Israel on August 24, |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2023 BIONDVAX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-37353 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37353 BIONDVAX PHARMACEU |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 10, 2023 BIONDVAX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-37353 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| May 4, 2023 |
Exhibit 99.1 NASDAQ: BVXV | May 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended |
|
| May 4, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 1, 2023 BIONDVAX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-37353 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 4, 2023 BIONDVAX PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) Israel 001-37353 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| April 17, 2023 |
Exhibit 3.1 COMPANIES LAW, 5759 – 1999 LIMITED SHARES COMPANY Articles of Association of BIONDVAX PHARMACEUTICALS LTD. 1. In these articles, except where the written content requires a different interpretation: “Law” As defined in the Interpretation Law, 5741 – 1981; “The Company” The abovementioned Company; “The Law” or the “Companies Law” The Companies Law, 5759 – 1999, as it shall be from time |
|
| April 17, 2023 |
Exhibit 10.21 |
|
| April 17, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-37353 BiondVax Pharmaceuticals Ltd |
|
| April 17, 2023 |
Employment Agreement dated September 5, 2018, between BiondVax Pharmaceuticals Ltd. and Elad Mark. EX-10.10 6 f10k2022ex10-10biondvax.htm EMPLOYMENT AGREEMENT DATED SEPTEMBER 5, 2018, BETWEEN BIONDVAX PHARMACEUTICALS LTD. AND ELAD MARK Exhibit 10.10 |
|
| April 17, 2023 |
Exhibit 10.9 |
|
| April 17, 2023 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 This section summarizes certain information regarding the ordinary shares, no par value (the “Ordinary Shares”), of BiondVax Pharmaceuticals Ltd. (the “Company”) and the American Depositary Shares (“ADSs”), each representing 400 Ordinary Shares. The following descriptions are a summary an |
|
| April 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BiondVax Pharmaceuticals Ltd. |
|
| April 17, 2023 |
Exhibit 14.1 BIONDVAX PHARMACEUTICAL LTD. CODE OF CONDUCT Introduction It is the policy of BiondVax Pharmaceuticals Ltd. (together with its subsidiaries, the “Company”) to conduct its affairs in accordance with all applicable laws, rules and regulations of the jurisdictions in which it does business. This Code of Business Conduct and Ethics (this “Code”) applies to the Company’s employees, officer |
|
| April 17, 2023 |
Exhibit 10.8 |
|
| April 17, 2023 |
As filed with the Securities and Exchange Commission on April 17, 2023 As filed with the Securities and Exchange Commission on April 17, 2023 Registration No. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-37353 CUSIP NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ |
|
| February 6, 2023 |
SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* BiondVax Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 09073Q204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| January 23, 2023 |
Exhibit 99.1 BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study ● COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 ● Data further strengthens value proposition of BiondVax’s COVID-19 NanoAb as prophylactic and therap |
|
| January 11, 2023 |
Exhibit 99.1 AMIR REICHMAN, CEO BIOTECH SHOWCASE | JANUARY 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and simil |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| January 9, 2023 |
Exhibit 99.1 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study · Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placebo · Result builds on recently announced data indicatin |
|
| January 9, 2023 |
6-K 1 ea171420-6kbiondvax.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerus |
|
| January 4, 2023 |
BiondVax CEO Issues Letter to Shareholders EX-99.1 2 ea171048ex99-1biondvax.htm LETTER TO SHAREHOLDERS Exhibit 99.1 BiondVax CEO Issues Letter to Shareholders Jerusalem, Israel – December 30, 2022 – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, today published a lett |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2023 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Is |
|
| January 4, 2023 |
SC 13G 1 bvxv0123.txt SABBY 13G BVXV 1.04.23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* BiondVax Pharmaceuticals Ltd. (Name of Issuer) ADSs (Title of Class of Securities) 09073Q105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| December 29, 2022 |
Exhibit 99.1 NASDAQ: BVXV | JANUARY 2023 2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as ?expect,? ?believe,? ?intend,? ?plan,? ?continue,? ?may,? ?will,? ?anticipate,? and similar expressions are inte |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2022 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
|
| December 27, 2022 |
BVXV / BiondVax Pharmaceuticals Ltd. / NACHT MARIUS - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5) BiondVax Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 09073Q105 (CUSIP Number) Angels Investments in Hi Tech Ltd. 42 Brandeis St. Tel Aviv, 6200157, Israel Telephone: +972.73.398.9560 (Name, Address |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December, 2022 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, |
|
| December 20, 2022 |
Underwriting Agreement, dated December 16, 2022, between the Company and Aegis Capital Corp. Exhibit 1.1 1,600,000 UNITS BIONDVAX PHARMACEUTICALS, LTD. UNDERWRITING AGREEMENT December 16, 2022 Aegis Capital Corp. 810 Seventh Avenue New York, New York 10019 Ladies and Gentlemen: The undersigned, BiondVax Pharmaceuticals, Ltd., a company incorporated under the laws of Israel (collectively with its Subsidiaries (as defined below), if any, the ?Company?), hereby confirms its agreement (this ? |
|
| December 20, 2022 |
Form of Non-Exchangeable Warrant. Exhibit 4.3 PURCHASE WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIONDVAX PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: December 20, 2022 Issue Date: December 20, 2022 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon t |
|
| December 20, 2022 |
Exhibit 4.2 PURCHASE WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIONDVAX PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: December 20, 2022 Issue Date: December 20, 2022 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon t |
|
| December 20, 2022 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-267648 PROSPECTUS 400,000 Units Each Consisting of One American Depositary Share and Two Warrants. Each to Purchase One American Depositary Share 1,200,000 Pre-Funded Units Each Consisting of One Pre-Funded Warrant and Two Warrants. Each to Purchase One American Depositary Share BiondVax Pharmaceuticals Ltd We are offering 400,000 units, each c |
|
| December 20, 2022 |
Exhibit 4.1 PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIONDVAX PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: December 20, 2022 Issue Date: December 20, 2022 THIS PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entit |
|
| December 20, 2022 |
BiondVax Announces Closing of $8 Million Underwritten Public Offering Exhibit 99.1 BiondVax Announces Closing of $8 Million Underwritten Public Offering JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) - via InvestorWire ? BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(?Company?), a biotechnology company, which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, tod |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2022 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
|
| December 19, 2022 |
BiondVax Announces Pricing of $8 Million Underwritten Public Offering Exhibit 99.1 BiondVax Announces Pricing of $8 Million Underwritten Public Offering JERUSALEM, Dec. 16, 2022 (GLOBE NEWSWIRE) - via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“Company”), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the pricing |
|
| December 14, 2022 |
Exhibit 4.5 PURCHASE WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIONDVAX PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: [], 20 Issue Date: December [], 2022 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms an |
|
| December 14, 2022 |
Exhibit 4.4 PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIONDVAX PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: [], 20 Issue Date: December [], 2022 THIS PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon t |
|
| December 14, 2022 |
BiondVax Regains Nasdaq Compliance Exhibit 99.1 BiondVax Regains Nasdaq Compliance Jerusalem Dec. 12, 2022 (GLOBE NEWSWIRE) - via InvestorWire ? BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (?BiondVax?), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announces today the receipt of formal notifications |
|
| December 14, 2022 |
6-K 1 ea170179-6kbiondvaxpharma.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2022 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English |
|
| December 14, 2022 |
As filed with the United States Securities and Exchange Commission on December 14, 2022. F-1/A 1 ea170090-f1a2biondvax.htm AMENDMENT NO. 2 TO FORM F-1 As filed with the United States Securities and Exchange Commission on December 14, 2022. Registration No. 333-267648 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BiondVax Pharmaceuticals Ltd. (Exact name of registrant as specifi |
|
| December 14, 2022 |
Form of Underwriting Agreement EX-1.1 2 ea170090ex1-1biondvax.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 [*] UNITS BIONDVAX PHARMACEUTICALS, LTD. UNDERWRITING AGREEMENT December [*], 2022 Aegis Capital Corp. 810 Seventh Avenue New York, New York 10019 Ladies and Gentlemen: The undersigned, BiondVax Pharmaceuticals, Ltd., a company incorporated under the laws of Israel (collectively with its Subsidiaries (as defined below), |
|
| December 14, 2022 |
CORRESP 1 filename1.htm AEGIS CAPITAL CORP. December 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: BiondVax Pharmaceuticals Ltd. Registration Statement on Form F-1 File No. 333-267648 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (th |
|
| December 14, 2022 |
Form of Non-Exchangeable Warrant Exhibit 4.6 PURCHASE WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIONDVAX PHARMACEUTICALS LTD. Warrant Shares: Initial Exercise Date: [], 20 Issue Date: December [], 2022 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms an |
|
| December 14, 2022 |
Articles of Association of BiondVax Pharmaceuticals Ltd. Exhibit 3.1 COMPANIES LAW, 5759 ? 1999 LIMITED SHARES COMPANY Articles of Association of BIONDVAX PHARMACEUTICALS LTD. 1. In these articles, except where the written content requires a different interpretation: ?Law? As defined in the Interpretation Law, 5741 ? 1981; ?The Company? The abovementioned Company; ?The Law? or the ?Companies Law? The Companies Law, 5759 ? 1999, as it shall be from time |
|
| December 14, 2022 |
Exhibit 10.14 C L I F F O R D CLIFFORD CHANCE LLP CHANCE Contract numbers (FI No.): 88205 91305 Serapis No.: 2015-0572 AMENDMENT AGREEMENT DATED 9 AUGUST 2022 FOR EUROPEAN INVESTMENT BANK AND BIONDVAX PHARMACEUTICALS LTD RELATING TO A FINANCE CONTRACT ORIGINALLY DATED 19 JUNE 2017 AND AS AMENDED FROM TIME TO TIME CONTENTS Clause Page 1. Definitions and Interpretation 1 2. Representations 2 3. Amen |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2022 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
|
| December 14, 2022 |
BiondVax Pharmaceuticals Ltd. Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel December 14, 2022 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BiondVax Pharmaceuticals Ltd. Registration Statement on Form F-1 Filed September 29, 2022, as amended Registration No. 333-267648 Ladies a |
|
| December 12, 2022 |
EX-FILING FEES 4 ea170014ex107-1biondvax.htm CALCULATION OF FILING FEE TABLES EXHIBIT 107 Calculation of Filing Fee Tables Form F-1 (Form Type) BiondVax Pharmaceuticals Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offe |
|
| December 12, 2022 |
Power of Attorney (included in signature page to Registration Statement). F-1/A 1 ea170014-f1a1biondvax.htm AMENDMENT NO. 1 TO FORM F-1 As filed with the United States Securities and Exchange Commission on December 12, 2022. Registration No. 333-267648 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BiondVax Pharmaceuticals Ltd. (Exact name of registrant as specifi |
|
| November 30, 2022 |
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update Jerusalem, Israel – November 30, 2022 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the q |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2022 Commission File Number: 001-37353 BIONDVAX PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, I |
